High blood pressure
A recent study performed at the Mayo Clinic in January 2020 show that treatments of (PEMF) Pulsed Electro-Magnetic Field Therapy substantially reduced blood pressure for individuals suffering with high blood pressure and hypertension.
Impact of pulsed electromagnetic field therapy on vascular function and blood pressure in hypertensive individuals
The present study investigated the impact of 12 weeks of pulsed electromagnetic field (PEMF) therapy on peripheral vascular function, blood pressure (BP), and nitric oxide in hypertensive individuals. Thirty hypertensive individuals (SBP > 130 mm Hg and/or MAP > 100 mm Hg) were assigned to either PEMF group (n = 15) or control group (n = 15). During pre-assessment, participants underwent measures of flowmediated dilation (FMD), BP, and blood draw for nitric oxide (NO). Subsequently, they received PEMF therapy 3x/day for 12 weeks and, at conclusion, returned to the laboratory for post-assessment. Fifteen participants from the PEMF group and 11 participants from the control group successfully completed the study protocol. After therapy, the PEMF group demonstrated significant improvements in FMD and FMDNOR (normalized to hyperemia), but the control group did not (P = .05 and P = .04, respectively). Moreover, SBP, DBP, and MAP were reduced, but the control group did not (P = .04, .04, and .03, respectively). There were no significant alterations in NO in both groups (P > .05). Twelve weeks of PEMF therapy may improve BP and vascular function in hypertensive individuals. Additional studies are needed to identify the mechanisms by which PEMF affects endothelial function.
Hypertension is a major cardiovascular risk factor, and approximately 50 million people suffer from this clinical syndrome in America.1 Hypertension is a modifiable risk factor, and a review of epidemiologic study and randomized controlled trial has revealed that lowering BP can reduce the incidence of cardiovascular disease and mortality.2 Non-pharmacological interventions are emphasized for BP regulation, and there is a need for new or complementary therapeutic interventions without eliciting adverse effects, such as increases in lipid and triglyceride levels,3 oxidative stress from pharmacological treatment which also increases the risk of other negative side effects,4 and development of medication resistance.5 In addition, endothelial vascular dysfunction has been highly associated with cardiovascular disease,6,7 and it is a common pathophysiological process in hypertension.8-11 Pulsed electromagnetic field (PEMF) therapy comprises of intermittent low-level electromagnetic currents directed toward the body. The therapy using low-frequency PEMF has been utilized in numerous studies and reported that it does not develop side effects.12,13 There is a growing interest in this type of therapeutic technique as a treatment for numerous chronic diseases. Previous studies have demonstrated a number of clinical beneficial effects of PEMF therapy, including improved osteoarthritis-related pain and stiffness14,15 and enhanced stimulation of osteoblast proliferation and differentiation for bone formation.16 Moreover, PEMF therapy may improve diabetic polyneuropathy in individuals with diabetes17 and can be effective for reducing postoperative pain and edema following plastic surgery.18 While these clinical studies have shown benefits for several targeted organs and injured tissues, the suggested mechanisms seem to collectively involve an upregulation of the binding of calcium-calmodulin (Ca2+–CaM) cascade to enhance nitric oxide (NO) with subsequent improvements in microcirculation. Accordingly, recent animal studies have shown that PEMF therapy directly enhances microcirculation.19-22 This may suggest that PEMF can be a simple non-invasive treatment option to improve peripheral vascular function and BP. Therefore, the present study investigated whether PEMF therapy for 12 weeks could improve endothelial vascular function, lower BP, and increase NO in hypertensive individuals.
Twelve weeks of PEMF therapy improved endothelial vascular function and reduced BP in hypertensive participants. This result may indicate that PEMF therapy can be a potential non-pharmacological and non-invasive strategy to manage vascular function and BP in cohorts with peripheral vascular disease as well as hypertension. However, since the optimal strength, frequency, and duration of electromagnetic field emittance have not been determined, therapeutic benefits may vary based on those variables. Accordingly, further studies should attempt to manipulate these variables while examining the putative mechanism(s) of action. Finally, larger clinical studies are needed to assess the clinical applications of PEMF therapy as a targeted non-pharmacological and non-invasive option and the influence of confounding factors (eg, obesity and age) on the effects of PEMF therapy
FOR A COMPLETE COPY OF THE STUDY CONTACT CLUB RECHARGE: 440-567-1146